Oruka Therapeutics (NASDAQ:ORKA) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Oruka Therapeutics (NASDAQ:ORKA) had its price target hoisted by stock analysts at Stifel Nicolaus from $47.00 to $72.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 80.00% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. BTIG Research raised their target price on Oruka Therapeutics from $63.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Guggenheim reaffirmed a “buy” rating and issued a $60.00 price target on shares of Oruka Therapeutics in a report on Friday. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday. UBS Group assumed coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 8th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.67.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $40.00 on Friday. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $41.19. The firm has a market capitalization of $1.94 billion, a PE ratio of -21.51 and a beta of -0.38. The business’s fifty day moving average price is $32.92 and its 200 day moving average price is $27.59.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. As a group, equities analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total transaction of $226,590.00. Following the sale, the insider owned 34,018 shares in the company, valued at approximately $1,101,162.66. The trade was a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 21,000 shares of company stock worth $663,530 in the last 90 days. 24.69% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its position in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $37,000. PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $67,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Oruka Therapeutics during the third quarter worth approximately $43,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.